1. Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. 
Epub 2018 Nov 27.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in 
BRAFi-Resistant Melanomas.

Garandeau D(#)(1), Noujarède J(#)(1), Leclerc J(#)(2), Imbert C(1), Garcia V(1), 
Bats ML(1), Rambow F(3), Gilhodes J(4), Filleron T(4), Meyer N(5), Brayer S(5), 
Arcucci S(1), Tartare-Deckert S(2), Ségui B(1), Marine JC(3), Levade T(1)(6), 
Bertolotto C(#)(2), Andrieu-Abadie N(#)(7).

Author information:
(1)Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III 
Paul-Sabatier, Inserm, Centre de Recherches en Cancérologie de Toulouse, 
Toulouse, France.
(2)Université Nice Sophia-Antipolis, Inserm, Centre Méditerranéen de Médecine 
Moléculaire, Nice, France.
(3)VIB, Center for the Biology of Disease, Leuven, Belgium.
(4)Bureau des essais cliniques, Institut Universitaire du Cancer de 
Toulouse-Oncopôle, Toulouse, France.
(5)Service de Dermatologie-Oncologie, Institut Universitaire du Cancer de 
Toulouse-Oncopôle, Toulouse, France.
(6)Laboratoire de Biochimie Métabolique, CHU Toulouse, France.
(7)Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III 
Paul-Sabatier, Inserm, Centre de Recherches en Cancérologie de Toulouse, 
Toulouse, France. nathalie.andrieu@inserm.fr.
(#)Contributed equally

BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the 
V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified 
sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant 
melanoma cell-autonomous resistance to BRAFi. Moreover, our results reveal a 
distinct sphingolipid profile, that is, a tendency for increased very long-chain 
ceramide species, in the plasma of patients with melanoma who achieve a response 
to BRAFi therapy as compared with patients with progressive disease. Treatment 
with BRAFi resulted in a strong decrease in S1PR1/3 expression in sensitive but 
not in resistant cells. Genetic and pharmacologic interventions, that increase 
ceramide/S1P ratio, downregulated S1PR expression and blocked BRAFi-resistant 
melanoma cell growth. This effect was associated with a decreased expression of 
MITF and Bcl-2. Moreover, the BH3 mimetic ABT-737 improved the antitumor 
activity of approaches targeting S1P-metabolizing enzymes in BRAFi-resistant 
melanoma cells. Collectively, our findings indicate that targeting the S1P/S1PR 
axis could provide effective therapeutic options for patients with melanoma who 
relapse after BRAFi therapy.

©2018 American Association for Cancer Research.

DOI: 10.1158/1535-7163.MCT-17-1141
PMID: 30482853 [Indexed for MEDLINE]